CGS-16949A VS MEGESTROL ACETATE IN POST-MENOPAUSAL WOMEN WITH BREAST CANCER

CGS-16949A 与醋酸甲地孕酮治疗绝经后乳腺癌女性的比较

• 批准号: 3763662
• 负责人: JAMES WERNZ
• 金额: --
• 依托单位: NEW YORK UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3763662
• 关键词: antineoplastics; breast neoplasms; clinical trials; combination chemotherapy; drug screening /evaluation; estrogen receptors; female; hormone inhibitor; hormone therapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; postmenopause; progesterone receptors; progestins; tamoxifen

The objective of this study is to compare the efficacy and safety of CGS-16949A vs megestrol acetate in post-menopausal women with estrogen-receptor positive and/or progesterone-receptor positive breast cancer (or estrogen-receptor unknown/progesterone-receptor unknown) who relapse while receiving adjuvant tamoxifen therapy.

本研究的目的是比较以下药物的有效性和安全性： CGS-16949A 与醋酸甲地孕酮治疗绝经后女性的疗效 雌激素受体阳性和/或孕激素受体阳性乳房 癌症（或雌激素受体未知/孕激素受体未知） 接受他莫昔芬辅助治疗时复发。